Spyre Therapeutics (SYRE) Shares Outstanding (Diluted Average) (2020 - 2026)

Spyre Therapeutics (SYRE) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $346045.0 in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 99.43% year-over-year to $346045.0; the trailing twelve-month figure through Mar 2026 stood at $346045.0 (down 99.43% YoY), and the FY2025 full-year result was $64.1 million, up 36.21% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $346045.0, down from $64.1 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $82.2 million in Q2 2022 and bottomed at $346045.0 in Q2 2025.
• The 5-year median for Shares Outstanding (Diluted Average) is $5.6 million (2023), against an average of $26.8 million.
• The widest annual swing landed in 2025, when Shares Outstanding (Diluted Average) surged 13689.66%; it then sank 99.43% in 2026.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $3.2 million in 2022, then surged by 114.0% to $6.9 million in 2023, then surged by 581.85% to $47.0 million in 2024, then jumped by 36.21% to $64.1 million in 2025, then plunged by 99.46% to $346045.0 in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $346045.0 (Q1 2026), $64.1 million (Q4 2025), and $346045.0 (Q3 2025), per Business Quant data.

Peer Comparison